IBIO · iBio, Inc.
$1.21
-0.02 (-1.63%)
At close · Sep 11
Going-concern doubt
— cleared Aug 28, 2026
The latest filing states the doubt was alleviated.
“The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern. In August 2025, the Company closed an underwritten public offering raising gross proceeds of approximately $50 million and in January 2026, the Company raised gross proceeds of approximately $26 million in a private placement. Additionally, the Company received gross proceeds of approximately $33.4 million from the exercise of warrants during the year ended June 30, 2026. Based on the total cash and cash equivalents, and investments in debt securities of approximately $88 million at June 30, 2026, the Company believes that its current cash position is sufficient to fund its operations for at least 12 months from the date of filing this Annual Report on Form 10-K for the year ended June 30, 2026 (the “Annual Report”).”View the 10-K filed Aug 28, 2026
Market Cap
$77.49M
Shares
64.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.21
Open$1.24
Day$1.20–1.24
52W close$0.79–3.07
Avg vol 30d651K
Short int5.2M · 8.1% float · 5.8d
Short vol72%
Last earningsSep 27, 2022
DataNov 2023–Sep 2026
Filing10-K · Aug 28
Raw chart and full-history price indicators begin at the captured split on Nov 29, 2023; bars on opposite sides are not compared.
Up next
filed Aug 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$300,000
Trailing 12 months
Net income (TTM)
−$33.04M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-35,141.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-30.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$56.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,112.7%
Year over year · more shares
Price change (1Y)
+39.2%
Trailing year
Short interest
8.1%
Latest settlement · 5.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−35%
below
Price vs 50-day avg
−15%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
18%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−42%
trailing
YTD return
−38%
this year
Relative strength
−60%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +16 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.09% of float · ▲ +3.5% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
55 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+82%
Y/Y
Free cash flow
$-23.8M
Quant / Vol
risk profile
Volatility
110%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−35%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
18%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +16 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.09% of float · ▲ +3.5% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
55 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 18%
Range high $3
vs 200-day avg -35%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IBIO
this stock
iBio, Inc.
|
$77.49M | -37.6% | -100.0% | — | 8.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Nov 29, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IBIO | -7.3% | -13.9% | -42.3% | -5.1% | -37.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -6.2% | -12.2% | -60.2% | -4.8% | -49.6% |
Key facts
CIK
1420720
CUSIP
451033708
13F (30d)
25 filings
25 filers
Visit website
Investor relations